pipeline is deep... very, very deep. Compared to other biotech buyouts this company is still cheap. Consider its pipeline. Nobody has a pipeline anywhere close to what this company has. Its viable and it only takes one drug to succeed. Could easily still be a double ... you never know. When it happens it will be happen fast ! Hang in there all you longs.
Pay no attention to the losing bashers who have been hiding under rocks for decades.